

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2009

(Rs.in Lakhs)

	Particulars	STANDALONE					CONSOLIDATED				
		Quarter ended 30.09.2009	Quarter Ended 30.09.2008	Period ended 30.09.2009	Period ended 30.09.2008	Year ended 31.03.2009	Quarter ended 30.09.2009	Quarter Ended 30.09.2008	Period ended 30.09.2009	Period ended 30.09.2008	Year ended 31.03.2009
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	22287	33122	42564	59729	119056	22534	33047	43117	59405	118034
	(b) Other Operating Income	362	258	1304	609	1293	212	258	1379	609	1280
	<u>Total Income</u>	22649	33380	43868	60338	120349	22746	33305	44496	60014	119314
2	<u>Expenditure:</u>										
	a. (Increase) / Decrease in Stock- in-Trade and Work-in-Progress	(2473)	(4020)	(4856)	(6821)	(9909)	(2607)	(4275)	(4657)	(7636)	(11847)
	b. Consumption of Raw Material	8946	14898	19523	27143	54265	9043	14897	19598	27259	54382
	c. Purchase of Traded Goods		0		0	0		0		0	
	d. Staff Cost	1654	1597	3441	3079	6192	1765	1698	3683	3277	6628
	e. Depreciation	1305	1193	2591	2266	4782	1306	1194	2593	2268	4785
	f. Other Expenditure										
	- Manufacturing Expenses	1703	1807	3415	3706	7872	1826	1807	3545	3816	8080
	- Other expenses	1887	2795	3541	5596	11598	1975	3129	3748	6154	12672
	g. Total	13022	18270	27655	34969	74800	13308	18450	28510	35138	74700
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	9627	15110	16213	25369	45549	9438	14855	15986	24876	44614
4	Other Income	314	258	599	426	1008	338	242	599	396	934

5	Profit before Interest & Exceptional Items (3+4)	9941	15368	16812	25795	46557	9776	15097	16585	25272	45548
6	Interest	300	183	383	379	723	302	184	385	380	725
7	Profit after Interest but before Exceptional Items (5-6)	9641	15185	16429	25416	45834	9474	14913	16200	24892	44823
8	Exceptional items -Tax Expense of earlier years (Refer Note No.3)	0	0	5404	0	0	0	0	5404	0	0
9	Profit from ordinary activities before Tax (7-8)	9641	15185	11025	25416	45834	9474	14913	10796	24892	44823
10	Tax Expense										
	- Current Tax	828	1272	1700	2017	2959	828	1272	1700	2017	2959
	- MAT Credit Entitlements	0	(164)	0	(495)	(319)	0	(164)	0	(495)	(319)
	- Deferred Tax	169	304	189	466	727	167	261	188	386	497
	- Fringe Benefit Tax	0	5	0	12	22	0	5	0	12	22
11	Net Profit from ordinary activities after Tax: (9-10)	8644	13768	9136	23416	42445	8479	13539	8908	22972	41664
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	8644	13768	9136	23416	42445	8479	13539	8908	22972	41664
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	2611	1294	2611	1294	1295	2611	1294	2611	1294	1295
15	Reserves excluding revaluation reserves					124884					122843
16	Earnings per Share										
a)	Basic Earnings Per Share before exceptional items Rs.	6.64	10.64	11.16	18.09	32.79	6.51	10.46	10.99	17.75	32.19
	Diluted Earnings Per Share before exceptional items Rs.	6.59	10.53	11.09	17.91	32.46	6.47	10.35	10.91	17.57	31.86
b)	Basic Earnings Per Share before extra-ordinary items Rs.	6.64	10.64	7.02	18.09	32.79	6.51	10.46	6.84	17.75	32.19
	Diluted Earnings Per Share before extra-ordinary items Rs.	6.59	10.53	6.97	17.91	32.46	6.47	10.35	6.79	17.57	31.86
c)	Basic Earnings Per Share after extra-ordinary items Rs.	6.64	10.64	7.02	18.09	32.79	6.51	10.46	6.84	17.75	32.19
	Diluted Earnings Per Share after extra-ordinary items Rs.	6.59	10.53	6.97	17.91	32.46	6.47	10.35	6.79	17.57	31.86

17	Public shareholding: - No. of shares - % of shareholding	61388395 47.02%	30139825 46.57%	61388395 47.02%	30139825 46.57%	30173725 46.59%	61388395 47.02%	30139825 46.57%	61388395 47.02%	30139825 46.57%	30173725 46.59%
18	Promoters and promoter group shareholding: a) pledged / encumbered b) non-encumbered: No. of shares Percentage of shares (as a % of the total shareholding of the promoter group) Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
		69168600 100%	34584300 100%	69168600 100%	34584300 100%	34584300 100%	69168600 100%	34584300 100%	69168600 100%	34584300 100%	34584300 100%
		52.98%	53.43%	52.98%	53.43%	53.41%	52.98%	53.43%	52.98%	53.43%	53.41%

NOTES:

1. The above results for the period ended 30th September 2009, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 30th October, 2009 and were subjected to "limited review" by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting notified under the Companies Act, 1956.
3. During the period, consequent to the recent clarificatory amendment to applicable income-tax provisions for SEZ Units made effective prospectively, an amount of Rs.5404 lakhs has been provided towards tax expense of earlier years, representing shortfall of tax provision on account of claims in respect of the SEZ Unit set up by the company, under exceptional item, as the same is not in the nature of provision for ordinary activities of the current period. Statutory auditors have qualified in the audit report for the year ended 31st March, 2009 about short provision of tax. The Company has provided the short provision during the period.
4. During the current quarter, the company has allotted 6,48,47,975 bonus shares of Rs.2 each to the members on 2nd August, 2009 and also allotted 8,61,045 equity shares of Rs.2/- each to the employees on exercise of their stock options.
5. The figures for the previous year/period have been reclassified/regrouped, wherever necessary. Earnings Per Share (EPS) for the previous year/period has been recomputed after considering the issue of bonus shares during the year.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.09.2009:
Opening: Nil, Received during the Quarter: 14, Resolved: 14, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 30-10-2009

Dr. Murali K. Divi
Chairman & Managing Director